Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dainippon Sumitomo Submits Lurasidone NDA, Preps For Marketing Scramble

This article was originally published in The Pink Sheet Daily

Executive Summary

Company will use newly acquired Sepracor sales force for the atypical antipsychotic.

You may also be interested in...



Cardiac Safety Could Be Distinguishing Point For Sunovion's New Antipsychotic Latuda

Lack of a cardiac safety signal looks to be a key selling point for Sunovion Pharmaceuticals' atypical antipsychotic Latuda (lurasidone).

Cardiac Safety Could Be Distinguishing Point For Sunovion's New Antipsychotic Latuda

Lack of a cardiac safety signal looks to be a key selling point for Sunovion Pharmaceuticals' atypical antipsychotic Latuda (lurasidone).

Dainippon submits atypical antpsychotic NDA

Dainippon Sumitomo submitted an NDA for its atypical antipsychotic lurasidone for schizophrenia, and the company likely is hoping its newly acquired Sepracor sales force is up to the challenge in a crowded, but still fruitful, market (1"The Pink Sheet" DAILY, Jan. 6, 2009). Dainippon Sumitomo Pharma America submitted the NDA Dec. 30, ahead of initial plans to file in the third quarter of 2010. The company attributes the earlier submission date to the positive results, and particularly the safety profile, established in two Phase III PEARL studies. PEARL 2 results released Aug. 26 showed lurasidone at both 40 mg/day and 120 mg/day to be significantly more effective than placebo. In a Sept. 3 call to discuss the Sepracor acquisition, Dainippon Sumitomo CEO Masayo Tada touted lurasidone's effect on weight gain compared to placebo and Lilly's Zyprexa (olanzapine), which was included in an active-comparator arm to establish assay sensitivity. Although the atypical antipsychotics are a mature class, side effect profiles and frequent switching mean there is still room on the market, and the field saw two newcomers in 2009, Vanda's Fanapt and Schering-Plough's (now Merck's) Saphris

Related Content

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel